Accelerate Diagnostics Inc. (NASDAQ:AXDX) was up 2.2% during trading on Wednesday . The stock traded as high as $23.53 and last traded at $22.76, with a volume of 594,993 shares trading hands. The stock had previously closed at $22.28.

Several equities research analysts recently commented on AXDX shares. BTIG Research restated a “buy” rating and set a $26.00 target price on shares of Accelerate Diagnostics in a research report on Sunday, May 15th. Piper Jaffray Cos. restated an “overweight” rating and set a $25.00 target price on shares of Accelerate Diagnostics in a research report on Monday, May 16th. JPMorgan Chase & Co. upped their target price on Accelerate Diagnostics from $17.00 to $25.00 and gave the company an “overweight” rating in a research report on Tuesday, August 9th. Finally, Zacks Investment Research lowered Accelerate Diagnostics from a “hold” rating to a “sell” rating in a research report on Wednesday, July 13th. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. Accelerate Diagnostics currently has an average rating of “Buy” and an average price target of $25.33.

The stock’s market cap is $1.18 billion. The stock has a 50-day moving average of $19.64 and a 200 day moving average of $14.73.

In other news, Director Jack W. Schuler purchased 88,316 shares of the company’s stock in a transaction on Friday, June 10th. The stock was purchased at an average price of $14.69 per share, with a total value of $1,297,362.04. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Jack W. Schuler purchased 101,272 shares of the company’s stock in a transaction on Thursday, June 9th. The shares were purchased at an average cost of $14.14 per share, with a total value of $1,431,986.08. The disclosure for this purchase can be found here.

Accelerate Diagnostics, Inc is an in vitro diagnostics company engaged in providing solutions that improve patient outcomes and lower healthcare costs through the diagnosis of serious infections. The Company’s technology platform is built to address these challenges by delivering testing of infectious pathogens in various patient sample types.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.